Back to Search Start Over

Microorganismos y perfiles de resistencia en aislamientos de infecciones quirúrgicas intraabdominales en un Hospital de Bogotá – Colombia, 2017 – 2018

Authors :
Isaza-Restrepo, Andres
Buitrago, Daniel Felipe
Guerrero Vergel, Alvaro Felipe
Isaza-Restrepo, Andres
Buitrago, Daniel Felipe
Guerrero Vergel, Alvaro Felipe
Source :
reponame:Repositorio Institucional EdocUR; instname:Universidad del Rosario; Watkins RR, Bonomo RA. Overview: Global and Local Impact of Antibiotic Resistance. Vol. 30, Infectious Disease Clinics of North America. 2016. p. 313–22.; Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: Science for intervention. Vol. 6, New Microbes and New Infections. 2015. p. 22–9.; Who. ORIGINAL : ENGLISH WHO Global Strategy for Containment of Antimicrobial Strategy for Containment of Antimicrobial Resistance. World Health [Internet]. 2001;WHO/CDS/CS:105. Available from:; Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, et al. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2017;37(1):71–84.; Alvarez CA, Yomayusa N, Leal AL, Moreno J, Mendez-Alvarez S, Ibañez M, et al. Nosocomial infections caused by community-associated methicillin-resistant Staphylococcus aureus in Colombia. Am J Infect Control. 2010;38(4):315–8.; Alvarez C, Cortes J, Arango A, Correa C, Leal A. [Anti-microbial resistance in intensive care units in Bogota, Colombia, 2001-2003]. Rev Salud Publica [Internet]. 2006;8 Suppl 1:86–101. Available from:; Leal AL, Eslava-Schmalbach J, Alvarez C, Buitrago G, Méndez M, Grupo para el Control de la Resistencia Bacteriana en Bogotá. [Endemic tendencies and bacterial resistance markers in third-level hospitals in Bogotá, Colombia]. Rev salud pública (Bogotá, Colomb [Internet]. 2006;8 Suppl 1:59–70. Available from:; Villegas M V, Correa A, Perez F, Miranda MC, Zuluaga T, Quinn JP, et al. Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagnostic Microbiol Infect Dis. 2004;49:217–22.; McGowan JE. Economic impact of antimicrobial resistance. Emerg Infect Dis. 2001;7(2):286–92.; Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35(1):89–95.; Coast J, Smith RD. Antimicrobial resistance: cost and containment. Expert Rev Anti Infect Ther [Internet]. 2003;1(2):241–51. Available from:; Mazuski JE, Solomkin JS. Intra-Abdominal Infections. Vol. 89, Surgical Clinics of North America. 2009. p. 421–37.; Davies J, Davies D. Origins and Evolution of Antibiotic Resistance. Microbiol Mol Biol Rev [Internet]. 2010;74(3):417–33. Available from:; Fonseca JD, Knight GM, McHugh TD. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Vol. 32, International Journal of Infectious Diseases. 2015. p. 94–100.; Deutschendorf C, Goldani LZ, Pires dos Santos R. Previous use of quinolones: A surrogate marker for first line anti-tuberculosis drugs resistance in HIV-infected patients? Brazilian J Infect Dis. 2012;16(2):142–5.; Koirala KD, Thanh DP, Thapa SD, Arjyal A, Karkey A, Dongol S, et al. Highly resistant Salmonella enterica serovar typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. Antimicrob Agents Chemother. 2012;56(5):2761–2.; Chaudhary AS. A review of global initiatives to fight antibiotic resistance and recent antibiotics׳ discovery. Acta Pharm Sin B. 2016;6(6):552–6.; Center for Disease Dynamics Economics & Policy. The State of the world’s antibiotics 2015. Cent Dis Dyn Econ Policy, CDDEP Washington, DC. 2015;1–84.; European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). [Internet]. Ecdc. 2014. 1-211 p. Available from:; Arias CA, Reyes J, Zúñiga M, Cortés L, Cruz C, Rico CL, et al. Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001-2002. J Antimicrob Chemother. 2003;51(1):59–68.; Villegas M V, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect [Internet]. 2008;14 Suppl 1:154–8. Available from:; GREBO. Manual De Actualizacion En Resistencia Bacteriana Y Normas Clsi M100 – S20. Control [Internet]. 2010;1–78. Available from:; Vallejo M, Cuesta DP, Flórez LE, Correa A, Llanos CE, Isaza B, et al. Características clínicas y microbiológicas de la infección intra-abdominal complicada en Colombia: un estudio multicéntrico. Rev Chil infectología [Internet]. 2016;33(3):261–7. Available from:; Cohen AL, Calfee D, Fridkin SK, Huang SS, Jernigan JA, Lautenbach E, et al. Recommendations For Metrics For Multidrug-Resistant Organisms In Healthcare Settings: SHEA/HICPAC Position Paper. Infect Control Hosp Epidemiol [Internet]. 2008;29(10):901–13. Available from:; Young PY, Khadaroo RG. Surgical site infections. Vol. 94, Surgical Clinics of North America. 2014. p. 1245–64.; Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. Erratum: The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. [World J Emerg Surg. 12, (2017) (29)] DOI: 10.1186/s13017-017-0141-6. World Journal of Emergency Surgery. 2017.; Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals. 2013.; Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016. Eur J Clin Microbiol Infect Dis. 2018;; Sartelli M, Abu-Zidan FM, Catena F, Griffiths EA, Di Saverio S, Coimbra R, et al. Global validation of the WSES Sepsis Severity Score for patients with complicated intra-abdominal infections: A prospective multicentre study (WISS Study). World J Emerg Surg. 2015;; Sinapidis D, Kosmas V, Vittoros V, Koutelidakis IM, Pantazi A, Stefos A, et al. Progression into sepsis: An individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis. 2018;; Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect (Larchmt). 2017;; Takesue Y, Kusachi S, Mikamo H, Sato J, Watanabe A, Kiyota H, et al. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan. J Infect Chemother. 2018;; Timsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vésin A, et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: Study protocol for a randomized controlled trial. Trials. 2013;; Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: A systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015;; Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: Results of a systematic literature review and meta-analysis. Open Forum Infectious Diseases. 2018.; Centers for Diasease Control and Prevention. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). Natl Cent Emerg Zoonotic Infect Dis. 2014;; Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. International Journal of Antimicrobial Agents. 2017.; Tischendorf J, De Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review. Am J Infect Control. 2016;; Ecdc. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015. Report. 2015.; Wilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ, Bonomo RA, et al. Carbapenem-resistant enterobacter cloacae in patients from the US veterans health administration, 2006–2015. Emerging Infectious Diseases. 2017.; Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clin Infect Dis. 2017;; Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016;; Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Research International. 2016.; Cattoir V, Giard JC. Antibiotic resistance in Enterococcus faecium clinical isolates. Expert Review of Anti-Infective Therapy. 2014.; Rubinstein E, Keynan Y. Vancomycin-resistant enterococci. Critical Care Clinics. 2013.; McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale Journal of Biology and Medicine. 2017.
Publication Year :
2019

Abstract

El conocimiento de las tasas regionales/locales de resistencia debe ser siempre un componente esencial del proceso de toma de decisiones clínicas cuando se decide el tratamiento empírico de la infección. Se encontraron microorganismos y perfiles de resistencia con características muy similares a los reportados en el resto del mundo, como microorganismos catalogados como ESKAPE principalmente relacionados con infecciones de origen intrahospitalario y con perfiles de resistencia que evidenciaban una baja resistencia respecto a los reportes referenciados.<br />Knowledge of regional/local rates of resistance should always be an essential component of the clinical decision-making process when deciding on the empirical treatment of an infection. Microorganisms and resistance profiles founded have similar characteristics to those reported in the rest of the world, such as microorganisms cataloged as ESKAPE, mainly related to infections of intrahospitalary origin and resistance profiles showed a low resistance with respect to the referenced reports.

Details

Database :
OAIster
Journal :
reponame:Repositorio Institucional EdocUR; instname:Universidad del Rosario; Watkins RR, Bonomo RA. Overview: Global and Local Impact of Antibiotic Resistance. Vol. 30, Infectious Disease Clinics of North America. 2016. p. 313–22.; Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: Science for intervention. Vol. 6, New Microbes and New Infections. 2015. p. 22–9.; Who. ORIGINAL : ENGLISH WHO Global Strategy for Containment of Antimicrobial Strategy for Containment of Antimicrobial Resistance. World Health [Internet]. 2001;WHO/CDS/CS:105. Available from:; Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, et al. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2017;37(1):71–84.; Alvarez CA, Yomayusa N, Leal AL, Moreno J, Mendez-Alvarez S, Ibañez M, et al. Nosocomial infections caused by community-associated methicillin-resistant Staphylococcus aureus in Colombia. Am J Infect Control. 2010;38(4):315–8.; Alvarez C, Cortes J, Arango A, Correa C, Leal A. [Anti-microbial resistance in intensive care units in Bogota, Colombia, 2001-2003]. Rev Salud Publica [Internet]. 2006;8 Suppl 1:86–101. Available from:; Leal AL, Eslava-Schmalbach J, Alvarez C, Buitrago G, Méndez M, Grupo para el Control de la Resistencia Bacteriana en Bogotá. [Endemic tendencies and bacterial resistance markers in third-level hospitals in Bogotá, Colombia]. Rev salud pública (Bogotá, Colomb [Internet]. 2006;8 Suppl 1:59–70. Available from:; Villegas M V, Correa A, Perez F, Miranda MC, Zuluaga T, Quinn JP, et al. Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagnostic Microbiol Infect Dis. 2004;49:217–22.; McGowan JE. Economic impact of antimicrobial resistance. Emerg Infect Dis. 2001;7(2):286–92.; Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35(1):89–95.; Coast J, Smith RD. Antimicrobial resistance: cost and containment. Expert Rev Anti Infect Ther [Internet]. 2003;1(2):241–51. Available from:; Mazuski JE, Solomkin JS. Intra-Abdominal Infections. Vol. 89, Surgical Clinics of North America. 2009. p. 421–37.; Davies J, Davies D. Origins and Evolution of Antibiotic Resistance. Microbiol Mol Biol Rev [Internet]. 2010;74(3):417–33. Available from:; Fonseca JD, Knight GM, McHugh TD. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Vol. 32, International Journal of Infectious Diseases. 2015. p. 94–100.; Deutschendorf C, Goldani LZ, Pires dos Santos R. Previous use of quinolones: A surrogate marker for first line anti-tuberculosis drugs resistance in HIV-infected patients? Brazilian J Infect Dis. 2012;16(2):142–5.; Koirala KD, Thanh DP, Thapa SD, Arjyal A, Karkey A, Dongol S, et al. Highly resistant Salmonella enterica serovar typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. Antimicrob Agents Chemother. 2012;56(5):2761–2.; Chaudhary AS. A review of global initiatives to fight antibiotic resistance and recent antibiotics׳ discovery. Acta Pharm Sin B. 2016;6(6):552–6.; Center for Disease Dynamics Economics & Policy. The State of the world’s antibiotics 2015. Cent Dis Dyn Econ Policy, CDDEP Washington, DC. 2015;1–84.; European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). [Internet]. Ecdc. 2014. 1-211 p. Available from:; Arias CA, Reyes J, Zúñiga M, Cortés L, Cruz C, Rico CL, et al. Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001-2002. J Antimicrob Chemother. 2003;51(1):59–68.; Villegas M V, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect [Internet]. 2008;14 Suppl 1:154–8. Available from:; GREBO. Manual De Actualizacion En Resistencia Bacteriana Y Normas Clsi M100 – S20. Control [Internet]. 2010;1–78. Available from:; Vallejo M, Cuesta DP, Flórez LE, Correa A, Llanos CE, Isaza B, et al. Características clínicas y microbiológicas de la infección intra-abdominal complicada en Colombia: un estudio multicéntrico. Rev Chil infectología [Internet]. 2016;33(3):261–7. Available from:; Cohen AL, Calfee D, Fridkin SK, Huang SS, Jernigan JA, Lautenbach E, et al. Recommendations For Metrics For Multidrug-Resistant Organisms In Healthcare Settings: SHEA/HICPAC Position Paper. Infect Control Hosp Epidemiol [Internet]. 2008;29(10):901–13. Available from:; Young PY, Khadaroo RG. Surgical site infections. Vol. 94, Surgical Clinics of North America. 2014. p. 1245–64.; Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. Erratum: The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. [World J Emerg Surg. 12, (2017) (29)] DOI: 10.1186/s13017-017-0141-6. World Journal of Emergency Surgery. 2017.; Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals. 2013.; Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016. Eur J Clin Microbiol Infect Dis. 2018;; Sartelli M, Abu-Zidan FM, Catena F, Griffiths EA, Di Saverio S, Coimbra R, et al. Global validation of the WSES Sepsis Severity Score for patients with complicated intra-abdominal infections: A prospective multicentre study (WISS Study). World J Emerg Surg. 2015;; Sinapidis D, Kosmas V, Vittoros V, Koutelidakis IM, Pantazi A, Stefos A, et al. Progression into sepsis: An individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis. 2018;; Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect (Larchmt). 2017;; Takesue Y, Kusachi S, Mikamo H, Sato J, Watanabe A, Kiyota H, et al. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan. J Infect Chemother. 2018;; Timsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vésin A, et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: Study protocol for a randomized controlled trial. Trials. 2013;; Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: A systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015;; Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: Results of a systematic literature review and meta-analysis. Open Forum Infectious Diseases. 2018.; Centers for Diasease Control and Prevention. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). Natl Cent Emerg Zoonotic Infect Dis. 2014;; Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. International Journal of Antimicrobial Agents. 2017.; Tischendorf J, De Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review. Am J Infect Control. 2016;; Ecdc. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015. Report. 2015.; Wilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ, Bonomo RA, et al. Carbapenem-resistant enterobacter cloacae in patients from the US veterans health administration, 2006–2015. Emerging Infectious Diseases. 2017.; Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clin Infect Dis. 2017;; Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016;; Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Research International. 2016.; Cattoir V, Giard JC. Antibiotic resistance in Enterococcus faecium clinical isolates. Expert Review of Anti-Infective Therapy. 2014.; Rubinstein E, Keynan Y. Vancomycin-resistant enterococci. Critical Care Clinics. 2013.; McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale Journal of Biology and Medicine. 2017.
Notes :
application/pdf, Spanish
Publication Type :
Electronic Resource
Accession number :
edsoai.on1090766346
Document Type :
Electronic Resource

Tools

Authors Abstract Subjects Details